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Introduction
Antimicrobial abuse is one of the major factors 
contributing to the development and maintenance 
of antimicrobial resistance in bacteria. The issue is 
of utmost importance in many developing countries, 
where the sale of antimicrobials is often unrestricted 
(Okeke et al., 2005).
In Egypt, Escherichia coli is among the most com-
mon pathogens isolated from patients with urinary 
tract infections and it has a high prevalence of resist-
ance to antibiotics (Shaheen et al., 2004; Mohamed 
Al-Agamy et al., 2006). 
Bacterial resistance to antimicrobial agents is a threat 
to public health in Egypt. The consequences of resist-
ance affect not only the ability to treat the infection, but 
also the cost and duration of treatment (Shaheen et al., 
2004; Mohamed Al-Agamy et al., 2006). 
Fluoroquinolone resistance is on the rise. The emer-
gence of this resistance in nearly all species of bacteria 
was documented soon after the introduction of these 
compounds for clinical use (Acar and Goldstein, 1997). 
Levofloxacin resistance has been shown to increase 
more than 5-fold in 6 years. Rapid emergence of resist-
ance may have been fuelled by the increase in the rate of 
levofloxacin prescribing (Johnson et al., 2008). A study 
showed that the annual rates of levofloxacin resist-
ance of E. coli were 29.49% in 2005, 26.51% in 2006, 
40.21% in 2007, 43.20% in 2008, and 31.75% in 2009 
(Jang et al., 2011). The persistent increase in fluoroqui-
nolone resistance rates influences patient management 
and demands a  change in some existing guidelines 
for the treatment (Paterson, 2004; Wagenlehner et al., 
2011; Han et al., 2012).
The overexpression of efflux pumps contributes 
to multidrug resistance (MDR) in E. coli. Almost all 
Gram-negative bacteria have genes for efflux pumps. 
Two transporters, AcrAB and MdfA, which belong to 
two distinct families of efflux pumps, have the ability to 
efflux quinolones in E. coli. Most of these efflux genes 
are either underexpressed or not expressed at all. When 
they are overexpressed, they are associated with MDR 
in E. coli (Yang, 2003; Yasufuku et al., 2011).
The AcrAB-TolC system of E. coli is among the 
better characterized resistance-nodulation-cell division 
superfamily (RND) systems. In addition to recognizing 
many fluoroquinolones, this system exports a diversity 
of agents including tetracycline, β-lactams, chloram-
phenicol, erythromycin, rifampicin, disinfectants, dyes, 
and organic solvents. AcrA is a lipoprotein situated in 
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the periplasm; the inner membrane protein, AcrB, is 
a  proton-motive-force transporter of the RND type. 
Strains lacking in the AcrAB proteins are hypersuscep-
tible to many quinolones; on the other hand, fluoroqui-
nolone-resistant efflux mutants frequently overproduce 
the periplasmic protein AcrA. Such mutants display 
decreased susceptibility to ciprofloxacin, tetracycline, 
ampicillin, and chloramphenicol. Removal or inacti-
vation of proteins that suppress expression of AcrAB 
(AcrR and AcrS) reduces fluoroquinolone susceptibility 
(Drlica et al., 2012).
MdfA is a paradigm of multidrug-resistance anti-
porters. It is a member of the major facilitator super-
family (MFS) and is a transmembrane-spanning inte-
gral inner membrane protein (Edgar and Bibi, 1997).
In laboratory-generated mutants, overexpression 
of the efﬂux pumps AcrAB or MdfA have been shown 
to cause three to six fold increase in ﬂuoroquinolone 
resistance (Yang, 2003). The simultaneous overexpres-
sion of AcrAB and MdfA results in synergistic increases 
in resistance to ﬂuoroquinolones (Yang, 2003).
The overexpression of AcrA and MdfA in quinolone 
resistance in E. coli has been thoroughly investigated, 
yet data about it in Egypt, up until the date this paper 
has been written, has been really scarce.
Our aim in this study was to investigate the relation 
between antibiotic resistance and the expression of the 
efflux pump genes in E. coli by real-time quantitative 
polymerase chain reaction (RT-qPCR).
Experimental
Material and Methods
E. coli strains and growth conditions. A total of 
28 non-duplicate E. coli isolates were used in this 
study obtained from patients with urinary tract infec-
tion (UTI) treated in Damanhour General Hospi-
tal, Damanhour, Egypt between the years 2013 and 
2014. Post treatment isolates were excluded from this 
study. The isolates were identified with conventional 
bioche mical tests. All isolates were deemed to be clini-
cally significant (> 105 CFU/ml). They were selected 
according to their sensitivity to levofloxacin in order 
to correlate their sensitivity profile with the over-
expression of efflux pump genes. E. coli isolates with 
intermediate susceptibility were not classified as being 
resistant. The strains were propagated at 37°C in Luria- 
Bertani (LB) broth.
Susceptibility testing. The following 12 antimicro-
bial discs were selected according to CLSI guidelines 
(CLSI, 2015): amoxicillin (AML), amoxicillin-clavu-
lanic acid (AMC), cefuroxim (CMX), cefalexin (CL), 
cefepime (FEP), ceftriaxone (CRO), chloramphenicol 
(C), gentamycin (CN) tetracycline (TE), levofloxacin 
(LVX), meropenem (MEM), azithromycin (AZM) 
(Oxoid Ltd., Basingstoke, United Kingdom) on Mueller- 
Hinton agar (Oxoid Ltd., Basingstoke, United King-
dom). Zone sizes were measured to the nearest milli-
metre. Using the published CLSI guidelines, the sus-
ceptibility or resistance of the organism to each drug 
tested were then determined. E. coli ATCC 25922 (LGC 
Standards GmbH, Wesel, Germany) was used as a con-
trol (CLSI, 2015).
Determination of the minimum inhibitory con-
centration (MIC) to levofloxacin. Determination of 
the MIC of levofloxacin was done by using the two-fold 
dilution method according to CLSI guidelines (CLSI, 
2015). MICs were performed in 96-well microplates 
(Greiner, Wemmel, Belgium). Briefly, serial two fold 
dilutions of 2x strength antibiotic were performed in 
sterile distilled water. An overnight culture of the tested 
isolate in Mueller-Hinton Broth (MHB) was diluted 
in fresh double strength MHB till it reaches the con-
centration of 105 CFU/ml.
Fifty µl suspension of the organism in double 
strength MHB was added to the well with 0.05 ml of the 
antibiotic solution, and the microtiter plates were incu-
bated aerobically at 35°C. The MIC was then defined 
as the lowest concentration of the antibiotic in which 
there is no visible growth after overnight incubation. 
Results were recorded in μg/ml after incubation at 35°C 
for 18  hours (CLSI breakpoints for levofloxacin are 
≤ 2 µg/ml for susceptibility and ≥ 8 µg/ml for resistance). 
RNA extraction and quantification of RNA expres- 
sion using RT-qPCR (Taylor et al., 2010). All E. coli 
isolates were cultured at 37°C for 14 h on MacConkey 
agar plates (Oxoid Ltd., Basingstoke, United Kingdom), 
then cultured in 4 ml of Luria-Bertani medium (Oxoid 
Ltd., Basingstoke, United Kingdom) for 8 h. Total RNA 
was obtained from mid-logarithmic growth-phase bac-
terial cultures with Isolate II RNA Micro Kit (Bioline, 
Michigan, USA) (Pfaffl et al., 2002; Keeney et al., 2008). 
Genomic DNA contamination was removed by an on-
column RNase-free DNase I digestion. RNA purity 
was assessed spectrophotometrically by measuring 
the OD260/280 ratio by NanoDrop™ 8000 Spectrophoto - 
meter (Thermo Fisher Scientific – Delaware, USA). 
RNA integrity was assessed by visualization of one large 
and one small band of RNA after electrophoresis (Fleige 
and Pfaffl, 2006). 
The quantification protocol was performed immedi-
ately following the quality control assessment. The acrA 
and mdfA genes were quantified by RT-qPCR using 
a SensiFAST™ SYBR No-ROX One-Step Kit (2x) (Bio-
line, United Kingdom) in a StepOne™ Real-Time PCR 
System (StepOne™ system, Applied biosystems, USA). 
The reaction mixture was prepared in a total volume 
of 20 µl dispensed in MicroAmp® optical microplates 
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(ThermoFisher Scientific, Michigan, USA). Each reac-
tion mixture contained 0.5 µM of both forward and 
reverse primers, 10 µl of SensiFAST™ SYBR No-ROX 
One-Step Kit (2x) mix, 0.2 µl of reverse transcriptase, 
0.4 µl of Ribosafe RNA inhibitor, 4 µl of template RNA, 
and nuclease-free water to complete the volume. The 
oligonucleotide primers for the amplification were 
adapted from prior studies and are listed in (Table I) 
(Swick et al., 2011; Yasufuku et al., 2011).
PCR-grade water was used as a negative control. 
Genomic DNA from the E. coli ATCC 25922 strain 
was the positive control. The melting curve analysis 
ensured that only a single PCR product was amplified. 
A no-RT control was included by omitting the reverse 
transcriptase from the reaction. 
Each sample was placed in triplicate on a 48-well 
plate and subjected to one-step reverse transcription at 
50°C for 30 min, 40 cycles of denaturation at 94°C for 
15 s, annealing at 50°C for 30 s and extension at 72°C 
for 30 s. The Cq means of almost all samples in our 
study were less than 30 (Yasufuku et al., 2011). 
Using the Applied biosystems stepone™ system 
software the relative quantification of the expression 
of the target genes was calculated relative to gapA, 
a housekeeping gene, and then the expression rate of 
each efflux pump gene was determined by using E. coli 
(ATCC 25922) as the control (Pfaffl et al., 2002; Bohnert 
et al., 2007). 
Correlation of overexpression of efflux pump 
genes with MICs of each antibiotic. The overexpres-
sion of efflux pump genes was identified as ≥ 2-fold 
gene expression compared to that of the standard strain 
E. coli (ATCC 25922) in qRT-PCR (Keeney et al., 2008). 
The correlation of the overexpression of efflux pump 
genes with the MICs of levofloxacin was then deter-
mined. The correlations between the pattern of resist-
ance and the expression of both genes together with 
the MICs of levofloxacin have also been determined.
Statistical analysis. Statistical analyses were per-
formed by using Statistical Package for Social Sciences 
(SPSS) software version 17 with Spearman’s correlation 
test; p < 0.05 was considered statistically significant.
Results
Susceptibility testing. Susceptibility testing for the 
12 antibiotics was performed according to CLSI guide-
lines (CLSI, 2015). It showed that 79% of the isolates 
were MDR. MDR is most commonly defined as resist-
ance to ≥ 3 classes of antibiotics (Magiorakos et al., 
2012). The resistance patterns of the isolates (the num-
ber of antibiotics to which each isolate is resistant) to 
the studied antibiotics are shown in (Table II).
mdfA F CGGCAACGATATGATTCAAC 523 Yasufuku et al., 2011
mdfA R CAGTGACAGTTTCTCGCCTA
acrA F CTCTCAGGCAGCTTAGCCCTAA 107 Swick et al., 2011
acrA R TGCAGAGGTTCAGTTTTGACTGTT
gapA F ACTTCGACAAATATGCTGGC 215 Yasufuku et al., 2011
gapA R CGGGATGATGTTCTGGGAA
Table I
Primers used in this study
Gene Primer (5’-3’) ReferenceAmplicon length(bp)
AML  0 (0) 1 (3.6) 27 (96.4)
AMC 10 (35.7) 6 (21.4) 12 (42.8)
CMX  6 (21.4) 4 (14.3) 18 (64.3)
CL  6 (21.4) 2 (7.1) 20 (71.4)
FEP 14 (50) 0 (0) 14 (50)
CRO 10 (35.7) 2 (7.1) 16 (57.1)
C 20 (71.4) 0 (0)  8 (28.6)
CN 14 (50) 0 (0) 14 (50)
TE 10 (35.7) 0 (0) 18 (64.3)
LEV  0 (0) 3 (10.7) 25 (89.3)
MEM 28 (100) 0 (0)  0 (0)
AZM  8 (28.6) 0 (0) 20 (71.4)
Table II 
Susceptibility of antimicrobial agents
Antibiotic
No. (%) of isolates (n = 28)
Susceptible Intermediate Resistant
Minimum Inhibitory Concentration (MIC) and 
gene expression. Determination of the MIC of levoflo-
xacin was done by using the two-fold dilution method 
according to CLSI guidelines (Clinical and Laboratory 
Standards Institute. 3rd ed. 2015). All the tested isolates 
(100%) were levofloxacin resistant. Results of determi-
nation of MIC of levofloxacin are shown in (Table III).
Expression of acrA and mdfA genes. Among the 
28 isolates, 23 isolates (82.1) % showed overexpression 
of mdfA ranging from 2–34.47 folds, and 22 (78.6%) 
showed overexpression of acrA ranging from 2–9.52 
folds (Table III).
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Correlation of overexpression with MIC and pat-
terns of antibiotic resistance. The overexpression of 
efflux pump genes was defined as ≥ 2-fold gene expres-
sion compared to that of the standard strain E. coli 
(ATCC 25922) in qRT-PCR. A strong positive correla-
tion of the overexpression of both of mdfA and acrA 
with MICs of levofloxacin was detected (Spearman 
correlation 0.93 and 0.72 respectively, P < 0.05) by biva-
riate analysis.
Moderate positive correlation was found between 
the expression of mdfA and the pattern of antimicrobial 
resistance of each isolate (Spearman correlation 0.45, 
P < 0.05). This was not the case with the expression of 
acrA where no significant correlation with the pattern 
of antimicrobial resistance was found.
Moderate positive correlation was also found 
between levofloxacin MIC and the pattern of antimi-
crobial resistance of each isolate (Spearman correlation 
0.45, P < 0.05)
Discussion
Multidrug resistance is a growing public health 
concern worldwide (Okeke et al., 2005). The increas-
ing incidence of resistance among pathogenic E. coli 
makes the treatment difficult with an unpredictable 
outcome (Kariuki et al., 2007). Resistance to quinolones 
has reached 50% in some parts of the world (Kronvall, 
2010). This leads to a challenge in the use of this class 
of drugs. It is now necessary to investigate the possible 
molecular mechanisms by which E. coli strains acquire 
antibiotic resistance in an attempt to prevent further 
spread of these kinds of resistant strains and prevent 
the occurrence of new resistant ones.
In the present study we examined 28 E. coli isolates, 
all isolates (100%) were levofloxacin resistant and 79% 
were MDR. Similar to our results, Swick et al. (2011) 
found that no isolate categorized as MDR was flouroqui-
nolone susceptible. They also suggested the possibility 
of an underlying correlation between fluoroquinolone 
resistance and MDR, this was confirmed in our study 
where moderate positive correlation was found between 
levofloxacin MIC and the pattern of antimicrobial resist-
ance of each isolate (Spearman correlation 0.45, P < 0.05)
There is a widespread, escalating use of fluoroqui-
nolones. Even contrary to guidelines that recommend 
them in only select situations, the frequent use of fluo-
roquinolone antibiotics has been observed in nearly 
all settings. Quinolone antibiotics now have exceeded 
sulfa antibiotics in recent years as the most commonly 
prescribed treatment for outpatient UTIs in women 
(Kallen et al., 2006). 
We quantified the expression of the efflux pump 
genes known to affect fluoroquinolone resistance 
in a  single quantitative study and we used gapA as 
a house keeping gene. Housekeeping genes provided 
internal controls, which were used as a measure of 
mRNA expression levels irrespective of growth condi-
tion (Szabo et al., 2004). Jandu et al. (2009) reported 
that the expression of gapA was similar when detected 
under four different growth conditions so it was chosen 
as an internal control for our study.
We found that most of the levofloxacin resistant 
isolates overexpressed both mdfA and acrA genes 
(82.1% and 78.6% respectively). This was with agree-
ment of other studies, where overexpression of acrA 
together with acrB led to a three- to six-fold increase 
in fluoroquinolone resistance, while augmenting the 
level of acrAB through the overexpression of the tran-
 1 8 32 2.52 2.66
 2 11 128 4.93 7.71
 3 11 32 2.49 0.43
 4 4 64 4.90 3.93
 5 10 128 11.95 9.18
 6 2 8 1.15 1.45
 7 6 8 1.03 0.89
 8 10 64 2.83 6.44
 9 9 64 3.47 9.52
10 4 32 1.70 8.18
11 10 256 34.47 2.55
12 9 256 11.45 15.1
13 6 128 4.07 8.65
14 8 32 2.6 3.05
15 11 64 3.96 2.87
16 3 32 1.78 2.43
17 9 128 7.76 7.98
18 11 64 2.94 3.32
19 8 256 5.58 6.93
20 10 32 2.67 3.32
21 2 8 1.06 0.95
22 10 128 7.93 7.39
23 4 32 2.55 1.89
24 9 64 4.32 3.99
25 6 32 2.78 2.09
26 10 32 3.65 1.24
27 8 128 6.44 7.84
28 6 64 3.99 2.33
Table III
Resistance pattern of strains, MIC of levofloxacin and analysis
of quantification of RNA expression using qRT-PCR
* Average of three independent replicates
Sample
no.
Resistance
pattern
MIC of
Levofloxacin
(μg/ml)
Expression of
mdfA* acrA*
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scriptional regulator, sdiA, resulted in about the same 
(approximately six-fold) increase in drug resistance. 
Yasufuku et al. (2011) revealed a significant correla-
tion of the overexpression of mdfA with higher MICs 
of levofloxacin (Rahmati et al., 2002; Yang, 2003).
In general the more severe the MDR phenotype, 
the higher the likelihood that the isolate also overex-
pressed acrAB (Nikaido and Pagès, 2012). Han et al. 
(2012) found that out of 89 patients with fluoroqui-
nolone resistant isolates, 49.4% overexpressed acrAB.
A synergy in quinolone resistance was shown when 
acrAB was overexpressed simultaneously with norE 
or mdfA. Deletion of acrAB alone and all of the three 
pumps together had the same effect on the susceptibil-
ity of fluoroquinolones. The authors also found that the 
strain with acrAB deletion were the most susceptible 
when compared to mutants strains with deletion in 
norE and/or mdfA. The maximum quinolone resistance 
mediated by efflux pumps was suggested to be ~10-
fold, irrespective of any increase in production of these 
pumps (Yang, 2003). 
Studies conducted with efflux pump deleted 
(ΔAcrAB) strain delayed the emergence of resistance 
suggesting that the inhibition of AcrAB efflux pump 
could be a strong strategy for slowing the development 
of resistance in clinically important Gram-negative bac-
teria (Singh et al., 2012)
In our study 17.9% and 21.4% of the levofloxacin 
resistant isolates didn’t show over expression of mdfA 
and acrA respectively, thus flouroquinolone resistance 
may be contributed to other mechanisms such as gyrase 
or topoisomerase IV mutations. Morgan-Linnell et al. 
(2009) reported mutations in gyrase and/topoisomerase 
IV in 100% of the high-level-resistant E. coli clinical iso-
lates, while over production of the efflux pump (AcrA) 
contributed approximately 33% to the overall quinolone 
resistance. As to the mdfA gene, one of the levofloxacin 
susceptible isolates showed very slight overexpression.
It should be noted that expression of pump genes can 
be induced by natural substrates encountered during 
infection. For example, indole and bile, which would be 
encountered in the mammalian gut, induce expression 
of acrAB in E. coli and Salmonella (Sun et al., 2014).
Though increased efflux pump expression correlates 
with increase in levofloxacin MIC, we did not compare 
expression of efflux pumps in levofloxacin sensitive 
strains. Thus, this has to be investigated as efflux pump 
expression might be high in these strains too if they 
are resistant to other antibiotics since both pumps are 
broad spectrum. Some studies have found that resist-
ance to antibiotics through the same efflux pump is 
common (Poole, 2005).
An approach of blocking the efflux pump protein 
or gene has been studied. This falls under the class of 
biological inhibition of efflux pumps. The efflux pumps 
could be switched off with the means of specific anti-
bodies (Yoshihara and Inoko, 2011). The genes encod-
ing these pumps or their regulators could be blocked 
by means of the antisense strategies. The antisense 
approach has been revealed to work for AcrAB efflux 
pump in E. coli and has also been patented (Oethinger 
and Levy, 2001; 2011).
Efflux pump inhibitors can also be used for the 
eva luation of the effect of efflux pumps on resistance 
emergence, however there are two major concerns with 
such inhibitors. First, some of these inhibitors have 
been found to be substrates of efflux pumps themselves, 
thus questioning their credibility (Lomovskaya and 
Bostian, 2006). Second, the concentrations required 
for efflux pump inhibitory activity are often associa-
ted with toxicity and hence, are not clinically relevant 
(Schmitz et al., 1998).
While, only one Gram-negative bacterial species has 
been evaluated in our study, it is imperative to investi-
gate other bacterial species to increase the clinical rele-
vance of our results. Different inhibitory techniques can 
be utilized to study the different efflux pumps. These 
should not only be effective against multiple efflux 
pumps in one bacterial species but also against efflux 
pumps in more than one bacterial species.
In conclusion, we demonstrated a significant posi-
tive correlation between the overexpression of AcrA 
and MdfA efflux pumps and the resistance to levofloxa-
cin in E. coli clinical isolates. These findings contribute 
to further understanding of the molecular mechanisms 
of efflux pump systems and how they contribute to 
antibiotic resistance and suggest that developing new 
EPI could lead to treatments for flouroquinolones 
resistant bacteria.
Resistance emergence presents a debilitating chal-
lenge in the management of infectious diseases. Data 
from this study might add to our understanding of 
resistance development. Our findings suggest that the 
inhibition of efflux pumps could be a potential strategy 
to thwart the problem of antibiotic resistance. Consid-
ering the genetic plasticity in the bacteria, these find-
ings just seem to be the tip of the iceberg and much 
needs to be unravelled in the future.
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